Sacituzumab govitecan

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Esophagogastric Adenocarcinoma

Conditions

Esophagogastric Adenocarcinoma

Trial Timeline

Apr 17, 2024 → Jan 7, 2026

NCT ID

NCT06123468

About Sacituzumab govitecan

Sacituzumab govitecan is a phase 1/2 stage product being developed by Gilead Sciences for Esophagogastric Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT06123468. Target conditions include Esophagogastric Adenocarcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06923826	Phase 2	Recruiting	Apr 15, 2025	Apr 1, 2030	Salivary Gland Cancer
NCT06665178	Phase 2	Recruiting	Mar 31, 2025	Dec 1, 2028	Breast Cancer
NCT06235216	Phase 2	Recruiting	Sep 13, 2024	Dec 1, 2027	Differentiated Thyroid Cancer
NCT06329869	Phase 2	Recruiting	Aug 1, 2024	Nov 1, 2027	Esophageal Squamous Cell Carcinoma
NCT06263543	Phase 2	Recruiting	Jun 17, 2024	Dec 1, 2026	Breast Cancer
NCT06123468	Phase 1/2	Completed	Apr 17, 2024	Jan 7, 2026	Esophagogastric Adenocarcinoma
NCT05833867	Phase 1	Recruiting	Apr 1, 2024	Oct 1, 2027	Localized Muscle Invasive Bladder Urothelial Carcinoma
NCT06028932	Phase 2	Active	Jan 8, 2024	Nov 1, 2027	Ovarian Carcinoma
NCT05552001	Phase 3	Recruiting	Oct 5, 2023	May 6, 2028	Triple Negative Breast Cancer
NCT05884320	Phase 2	Recruiting	Jul 27, 2023	Jul 31, 2028	Gland
NCT05581589	Phase 2	Recruiting	Jun 15, 2023	Apr 30, 2027	Muscle Invasive Bladder Carcinoma
NCT05838521	Phase 2	Recruiting	Jun 2, 2023	Jun 1, 2028	Cervical Cancer
NCT04647916	Phase 2	Active	Jun 8, 2021	Dec 1, 2028	Anatomic Stage IV Breast Cancer AJCC v8
NCT04251416	Phase 2	Active	Mar 17, 2020	Feb 1, 2027	Endometrial Carcinoma
NCT03995706	Phase 1	Completed	Jul 17, 2019	Mar 20, 2024	Glioblastoma
NCT03725761	Phase 2	Active	Oct 24, 2018	Sep 1, 2027	Prostate Cancer

Competing Products

6 competing products in Esophagogastric Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO	Daiichi Sankyo	Phase 1/2	41
Pembrolizumab + Trastuzumab + FLOT	Merck	Phase 2	52
bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib	Roche	Phase 2/3	65
Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo	Amgen	Phase 1/2	40
regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin	Bristol Myers Squibb	Phase 2	51
18F-BMS-986229 Injection + IV 18F-BMS-986229	Bristol Myers Squibb	Pre-clinical	22

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved